Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets.A Clear View of Who We AreA Message From Our CEO, Erik EmersonGood mor…